RxDoctor Payments Data

Rodrigo Vazquez Guillamet, MD

Pulmonary Disease · Saint Louis, MONPI 1609029917

Payments from drug & device makers

What this record shows

This record is dominated by education: $27 of the $41 with a category attached, or 66.1%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.

$41in general payments, 2019–2025

Across 3 payments — averaging $13.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41
$191,800in research payments, 2019–2025

Across 10 payments — averaging $19,180 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$129K
  • AstraZeneca$62K

What the payments were for

  • Food & beverage$1434%
  • Education$2766%

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$41

How this compares

$41 in reported general payments places this provider in the 10th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$113,624
Medicare patients
275
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab20$91,402
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$80,727
Spiriva HandihalerTiotropium Bromide28$24,020
EliquisApixaban29$20,131
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$19,636
Valganciclovir Hcl84$16,256
Breo ElliptaFluticasone/Vilanterol38$16,067
Tacrolimus149$15,015
Voriconazole29$12,236
RestasisCyclosporine15$9,601
LokelmaSodium Zirconium Cyclosilicate20$9,177
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$6,517
SymbicortBudesonide/Formoterol Fumarate20$5,709
Azithromycin302$4,217
Atovaquone12$3,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Symbicort$41$14,88640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →